Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Abel Salazar Biomedical Sciences Institute (ICBAS), University of Porto, Porto, Portugal; IPATIMUP, Institute of Molecular Pathology and Immunology of University of Porto, Porto, Portugal.
Department of Anatomical Pathology, St Vincent's Hospital, Sydney, and University of New South Wales Sydney and University of Notre Dame, Sydney, Australia.
J Am Soc Cytopathol. 2023 Jul-Aug;12(4):251-257. doi: 10.1016/j.jasc.2023.04.002. Epub 2023 Apr 7.
The International Academy of Cytology has joined with the International Agency for Research on Cancer to bring together a group of experts in lung cytopathology to develop a WHO Reporting System for Lung Cytopathology (WHO System). This System aims to improve and standardize the reporting of cytopathology, facilitate communication between cytopathologists and clinicians, and improve patient care. The WHO System describes 5 categories for reporting lung cytopathology: 'Insufficient/Inadequate/Nondiagnostic', 'Benign', 'Atypical', 'Suspicious for malignancy', and 'Malignant', each one with a clear descriptive term, a definition, a risk of malignancy, and a suggested management algorithm. The key diagnostic cytopathologic features of each of the lesions within each category have been established by consensus through an Expert Editorial Board, who are also the authors of this review and selected for each reporting system and chosen based on their expertise in the field and/or diversity of geographical representation. Many other co-authors from around the world also contributed. The assignment of writing and editing responsibilities used the same model as that used for the WHO Classification of Tumours (https://whobluebooks.iarc.fr/about/faq/). The WHO System provides the best practice application of ancillary testing, including immunocytochemistry and molecular pathology, and guides in sampling and processing techniques to optimize the handling and preparation of specimens. The WHO System was created by the authors to be applicable globally and is based on cytomorphology with possibilities for additional diagnostic management of the patient. The authors are aware that local medical and pathology resources would differ, especially in low- and middle-income countries. The WHO Tumour Classification for Thoracic Tumors, Fifth Edition, is directly accessible through the online WHO System.
国际细胞学学会与国际癌症研究机构合作，召集了一组肺细胞病理学专家，制定了世界卫生组织肺细胞病理学报告系统（WHO 系统）。该系统旨在提高和规范细胞病理学报告，促进细胞病理学家与临床医生之间的沟通，并改善患者的护理。WHO 系统为肺细胞病理学报告描述了 5 个类别：“不足/不充分/无法诊断”、“良性”、“非典型”、“疑似恶性”和“恶性”，每个类别都有明确的描述性术语、定义、恶性风险和建议的管理算法。每个类别的每个病变的关键诊断细胞学特征都是通过专家编辑委员会的共识建立的，他们也是本综述的作者，并根据他们在该领域的专业知识和/或地理代表性的多样性为每个报告系统选择。来自世界各地的许多其他合著者也做出了贡献。写作和编辑责任的分配使用了与世界卫生组织肿瘤分类（https://whobluebooks.iarc.fr/about/faq/）相同的模式。WHO 系统提供了辅助检测（包括免疫细胞化学和分子病理学）的最佳实践应用，并指导采样和处理技术，以优化标本的处理和准备。WHO 系统是由作者为全球应用而创建的，基于细胞形态学，并为患者的额外诊断管理提供了可能性。作者意识到，当地的医疗和病理资源会有所不同，尤其是在低收入和中等收入国家。第五版《世界卫生组织胸部肿瘤分类》可通过在线 WHO 系统直接访问。
